Novo's weekly diabetes drug clears another Phase III hurdle

Novo Nordisk's ($NVO) in-development weekly diabetes treatment met its goals in a second Phase III trial, beating AstraZeneca's ($AZN) Bydureon in a 56-week study. In the trial, Novo's semaglutide charted a statistically significant improvement in blood sugar over AstraZeneca's weekly treatment in patients with Type 2 diabetes. The study is part of a 6-trial effort designed to support global approvals for semaglutide. In the first late-stage trial, the subcutaneous injection got about 73% of patients to their goal blood sugar levels, beating out placebo's 25%. More